We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Fibrocell is enlisting Castle Creek Pharma’s help to push its midphase gene therapy for a rare genetic disorder through the clinic and onto the market.